University of Cambridge invites applications for a 4-year PhD studentship starting 1 October 2027 in the Department of Pathology, with the AstraZeneca Discovery Centre at Cambridge. The project focuses on manipulating peptide-bond skipping sequences (2A) for protein engineering, with supervision by Prof. Andrew Firth and Dr.
Giovanni Ciotta. The student will work across two sites, gaining exposure to molecular biology, ribosome profiling, and bioinformatics.
#J-18808-Ljbffr
PhD: Engineered 2A Peptides for Biotech in Cambridge employer: University of Cambridge
The University of Cambridge offers a dynamic and collaborative work environment, particularly within the Department of Oncology, where you will play a pivotal role in advancing cancer research. With a strong emphasis on employee growth, you will have access to professional development opportunities and the chance to work alongside leading experts in the field. The university's commitment to innovation and excellence ensures that your contributions will have a meaningful impact on clinical care and research outcomes.
